PTJ
SYRE icon

Paul Tudor Jones’s Spyre Therapeutics SYRE Stock Holding History

Paul Tudor Jones’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Sell
2,645
-5,719
-68% -$417K ﹤0.01% 3247
2026
Q1 		$422K Sell
8,364
-1,763
-17% -$66.5K ﹤0.01% 2927
2025
Q4 		$332K Buy
+10,127
New +$265K ﹤0.01% 2984
2024
Q4 		– Sell
-31,138
Closed -$916K – 3492
2024
Q3 		$916K Buy
+31,138
New +$867K ﹤0.01% 1676

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Paul Tudor Jones's SYRE Position: Q2 2026 in Review

Paul Tudor Jones reduced its Spyre Therapeutics (SYRE) stake by 68% in Q2 2026, selling an estimated $417K and leaving 2,645 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #3247.

Paul Tudor Jones first reported a position in SYRE in Q3 2024 and has held it in 4 quarters since. The position peaked at $916K in Q3 2024. 263 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Paul Tudor Jones held 2,645 shares of Spyre Therapeutics worth $235K as of Q2 2026.
  • Paul Tudor Jones sold 5,719 Spyre Therapeutics shares in Q2 2026, an estimated $417K.
  • Spyre Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #3247 holding.
  • Paul Tudor Jones first reported a position in Spyre Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Paul Tudor Jones's Spyre Therapeutics position peaked at $916K in Q3 2024.
  • 263 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.